BIO-TECHNE Corp (TECH)
Every FINRA and SEC series the site collects for BIO-TECHNE Corp: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
6.5M
Short interest
settlement 2026-08-14
2.3
Days to cover
-30.3% vs prior
39.1%
Short share of volume
2026-09-11
8,190
Fails to deliver
settlement 2026-08-11
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in TECH is 6,463,327 shares, down 5,660,121 shares over the last month. Over the last 48 readings it ranged from 3,173,267 shares (31 October 2024) to 18,204,307 shares (15 June 2026). At the reported average volume of 2.9M shares a day that is 2.3 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/tech" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 6,463,327 | -30.3% | 2,850,913 | 2.27 |
| 2026-07-31 | 9,277,342 | -23.5% | 3,964,369 | 2.34 |
| 2026-07-15 | 12,123,448 | -23.8% | 5,339,634 | 2.27 |
| 2026-06-30 | 15,915,631 | -12.6% | 10,806,094 | 1.47 |
| 2026-06-15 | 18,204,307 | +31.5% | 2,955,086 | 6.16 |
| 2026-05-29 | 13,846,089 | -4.9% | 2,788,250 | 4.97 |
| 2026-05-15 | 14,553,011 | +9.1% | 3,959,564 | 3.68 |
| 2026-04-30 | 13,338,470 | -4.7% | 1,997,784 | 6.68 |
| 2026-04-15 | 14,001,926 | -0.7% | 1,965,228 | 7.12 |
| 2026-03-31 | 14,099,778 | +14.1% | 2,118,068 | 6.66 |
| 2026-03-13 | 12,352,658 | +16.8% | 2,485,940 | 4.97 |
| 2026-02-27 | 10,579,001 | -6.5% | 2,150,126 | 4.92 |
| 2026-02-13 | 11,308,392 | +14.9% | 2,872,427 | 3.94 |
| 2026-01-30 | 9,838,546 | -5.0% | 2,358,971 | 4.17 |
| 2026-01-15 | 10,356,637 | +3.1% | 2,301,455 | 4.50 |
| 2025-12-31 | 10,044,054 | +6.7% | 1,399,718 | 7.18 |
| 2025-12-15 | 9,414,943 | +1.8% | 1,778,286 | 5.29 |
| 2025-11-28 | 9,250,239 | -0.2% | 1,706,315 | 5.42 |
| 2025-11-14 | 9,265,811 | +22.1% | 2,402,060 | 3.86 |
| 2025-10-31 | 7,588,721 | +9.4% | 1,756,448 | 4.32 |
| 2025-10-15 | 6,939,394 | +28.9% | 2,682,825 | 2.59 |
| 2025-09-30 | 5,384,729 | +2.1% | 2,681,022 | 2.01 |
| 2025-09-15 | 5,273,911 | +2.9% | 2,155,931 | 2.45 |
| 2025-08-29 | 5,124,437 | -11.2% | 1,946,496 | 2.63 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of TECH volume is 39.1%, up 9.5 points over the last five sessions. Over the last 52 readings it ranged from 5.5% (31 July 2026) to 66.7% (27 August 2026). The latest reading is 9.1 points above the 30-session average of 30.0%, on 655K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 256K | 655K | 39.1% | 3,225 |
| 2026-09-10 | 329K | 731K | 45.0% | 3,102 |
| 2026-09-09 | 184K | 412K | 44.6% | 0 |
| 2026-09-08 | 215K | 515K | 41.8% | 523 |
| 2026-09-04 | 164K | 712K | 23.1% | 2,902 |
| 2026-09-03 | 258K | 872K | 29.6% | 467 |
| 2026-09-02 | 158K | 433K | 36.5% | 25 |
| 2026-09-01 | 431K | 866K | 49.8% | 1,522 |
| 2026-08-31 | 272K | 639K | 42.5% | 5 |
| 2026-08-28 | 293K | 553K | 52.9% | 4,561 |
| 2026-08-27 | 382K | 572K | 66.7% | 411 |
| 2026-08-26 | 192K | 460K | 41.9% | 83 |
| 2026-08-25 | 156K | 556K | 28.0% | 48 |
| 2026-08-24 | 101K | 398K | 25.4% | 107 |
| 2026-08-21 | 868K | 1.9M | 46.0% | 564 |
| 2026-08-20 | 541K | 1.5M | 35.0% | 200 |
| 2026-08-19 | 221K | 604K | 36.7% | 3,022 |
| 2026-08-18 | 205K | 1.3M | 15.5% | 1,212 |
| 2026-08-17 | 174K | 913K | 19.1% | 351 |
| 2026-08-14 | 154K | 911K | 16.9% | 10,538 |
| 2026-08-13 | 196K | 704K | 27.8% | 1,255 |
| 2026-08-12 | 93K | 813K | 11.4% | 8,429 |
| 2026-08-11 | 271K | 1.5M | 18.3% | 5,263 |
| 2026-08-10 | 112K | 1.1M | 9.8% | 159 |
| 2026-08-07 | 601K | 1.7M | 36.0% | 237 |
| 2026-08-06 | 179K | 856K | 20.9% | 15,466 |
| 2026-08-05 | 82K | 509K | 16.2% | 41 |
| 2026-08-04 | 108K | 1.0M | 10.5% | 299 |
| 2026-08-03 | 146K | 1.7M | 8.7% | 16,091 |
| 2026-07-31 | 121K | 2.2M | 5.5% | 421 |
Fails to deliver
SEC, by settlement date. JSONAs of 11 August 2026, the fails-to-deliver balance in TECH is 8,190 shares, up 6,333 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (3 June 2026) to 252,963 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-11 | 8,190 | $72.12 | $591K |
| 2026-08-05 | 1,857 | $72.09 | $134K |
| 2026-08-04 | 14,608 | $72.14 | $1.1M |
| 2026-08-03 | 1,562 | $72.09 | $113K |
| 2026-07-22 | 98 | $71.63 | $7K |
| 2026-06-30 | 252,963 | $70.90 | $17.9M |
| 2026-06-29 | 63,201 | $71.00 | $4.5M |
| 2026-06-26 | 69,386 | $70.70 | $4.9M |
| 2026-06-25 | 49,705 | $58.88 | $2.9M |
| 2026-06-24 | 273 | $56.26 | $15K |
| 2026-06-18 | 97 | $55.00 | $5K |
| 2026-06-16 | 2 | $56.17 | $112 |
| 2026-06-15 | 1,406 | $54.00 | $76K |
| 2026-06-12 | 6,534 | $54.02 | $353K |
| 2026-06-11 | 36,081 | $52.50 | $1.9M |
| 2026-06-10 | 1 | $54.41 | $54 |
| 2026-06-09 | 662 | $52.65 | $35K |
| 2026-06-05 | 29,623 | $53.18 | $1.6M |
| 2026-06-04 | 73,563 | $50.85 | $3.7M |
| 2026-06-03 | 1 | $49.77 | $50 |
| 2026-06-01 | 1,913 | $51.68 | $99K |
| 2026-04-29 | 6,330 | $53.51 | $339K |
| 2026-04-27 | 515 | $54.19 | $28K |
| 2026-04-15 | 3 | $58.66 | $176 |
| 2026-04-09 | 11 | $55.21 | $607 |
| 2026-04-08 | 45,868 | $53.83 | $2.5M |
| 2026-04-07 | 1,839 | $53.80 | $99K |
| 2026-04-06 | 50,152 | $53.13 | $2.7M |
| 2026-04-01 | 129 | $52.26 | $7K |
| 2026-03-31 | 98,051 | $52.04 | $5.1M |
Insider trades
SEC Form 4, newest first, 50 of 76 shown. JSONNo open-market insider trades were reported for TECH in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: Kelderman Kim (Chief Executive Officer) on 2026-08-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-15 | Kelderman Kim | Chief Executive Officer | Tax withholding | 11K | $72.40 | $783K | 83K |
| 2026-08-15 | Kelderman Kim | Chief Executive Officer | Option exercise | 21K | $0.00 | $0 | 94K |
| 2026-08-15 | Hippel James | CFO | Tax withholding | 4K | $72.40 | $312K | 170K |
| 2026-08-15 | Hippel James | CFO | Option exercise | 10K | $0.00 | $0 | 174K |
| 2026-08-15 | Geist William | PRESIDENT, PROTEIN SCIENCES | Tax withholding | 2K | $72.40 | $143K | 25K |
| 2026-08-15 | Geist William | PRESIDENT, PROTEIN SCIENCES | Option exercise | 6K | $0.00 | $0 | 27K |
| 2026-08-15 | Bohnen Shane | SVP - General Counsel | Tax withholding | 1K | $72.40 | $97K | 10K |
| 2026-08-15 | Bohnen Shane | SVP - General Counsel | Option exercise | 4K | $0.00 | $0 | 12K |
| 2026-08-15 | Crouse Steven C. | President - Diag & Spatial Bi | Tax withholding | 2K | $72.40 | $141K | 10K |
| 2026-08-15 | Crouse Steven C. | President - Diag & Spatial Bi | Option exercise | 5K | $0.00 | $0 | 12K |
| 2026-08-15 | Herr Amy E. | n/a | Tax withholding | 213 | $72.40 | $15K | 576 |
| 2026-08-15 | Herr Amy E. | n/a | Option exercise | 589 | $0.00 | $0 | 789 |
| 2026-07-29 | Hippel James | CFO | Tax withholding | 51K | $72.03 | $3.7M | 165K |
| 2026-07-29 | Hippel James | CFO | Option exercise | 62K | $47.60 | $3.0M | 216K |
| 2026-07-28 | Kelderman Kim | Chief Executive Officer | Tax withholding | 29K | $72.07 | $2.1M | 72K |
| 2026-07-28 | Kelderman Kim | Chief Executive Officer | Option exercise | 35K | $47.60 | $1.7M | 101K |
| 2026-07-23 | Bohnen Shane | SVP - General Counsel | Tax withholding | 344 | $71.77 | $25K | 7K |
| 2026-07-23 | Bohnen Shane | SVP - General Counsel | Option exercise | 448 | $47.60 | $21K | 8K |
| 2026-05-08 | Herr Amy E. | n/a | Sell | 7K | $48.28 | $320K | 200 |
| 2026-05-08 | Herr Amy E. | n/a | Option exercise | 7K | $47.60 | $316K | 7K |
| 2026-05-05 | Hippel James | CFO | Tax withholding | 57K | $56.68 | $3.2M | 154K |
| 2026-05-05 | Hippel James | CFO | Option exercise | 62K | $47.60 | $3.0M | 211K |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Tax withholding | 7K | $56.68 | $400K | 7K |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Option exercise | 8K | $47.60 | $400K | 14K |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Tax withholding | 24K | $56.68 | $1.4M | 66K |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Option exercise | 27K | $47.60 | $1.3M | 90K |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Tax withholding | 1K | $58.58 | $80K | 63K |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Option exercise | 11K | $0.00 | $0 | 64K |
| 2026-04-22 | Hippel James | CFO | Tax withholding | 56K | $58.58 | $3.3M | 149K |
| 2026-04-22 | Hippel James | CFO | Option exercise | 62K | $0.00 | $0 | 205K |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Tax withholding | 32K | $58.66 | $1.9M | 53K |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Option exercise | 37K | $0.00 | $0 | 85K |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Tax withholding | 740 | $53.13 | $39K | 6K |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Option exercise | 2K | $0.00 | $0 | 7K |
| 2026-02-17 | Herr Amy E. | n/a | Sell | 2K | $59.10 | $117K | 200 |
| 2026-02-03 | Herr Amy E. | n/a | Tax withholding | 16 | $64.63 | $1K | 2K |
| 2026-02-03 | Herr Amy E. | n/a | Option exercise | 38 | $0.00 | $0 | 2K |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Tax withholding | 2K | $64.09 | $107K | 8K |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Option exercise | 5K | $0.00 | $0 | 9K |
| 2025-11-03 | Kelderman Kim | Chief Executive Officer | Tax withholding | 2K | $62.57 | $144K | 49K |
| 2025-11-03 | Hippel James | CFO | Tax withholding | 12K | $62.57 | $742K | 143K |
| 2025-11-03 | Hippel James | CFO | Option exercise | 12K | $0.00 | $0 | 155K |
| 2025-11-03 | Hippel James | CFO | Option exercise | 13K | $0.00 | $0 | 143K |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Tax withholding | 5K | $62.57 | $283K | 21K |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Option exercise | 10K | $0.00 | $0 | 25K |
| 2025-10-30 | Bushman Julie L | n/a | Grant | 2K | $0.00 | $0 | 9K |
| 2025-10-30 | KEEGAN JOSEPH D | n/a | Grant | 2K | $0.00 | $0 | 15K |
| 2025-10-30 | HIGGINS JOHN L | n/a | Grant | 2K | $0.00 | $0 | 67K |
| 2025-10-30 | Seth Alpna | n/a | Grant | 2K | $0.00 | $0 | 15K |
| 2025-10-30 | Herr Amy E. | n/a | Grant | 2K | $0.00 | $0 | 3K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON2 holders above 5% have filed on TECH, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 8.1% of the class (12,754,784 shares), filed 2026-08-06 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13G/Ano. 1 | FMR LLCparent holding company | 12.8M | 8.1% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 12.8M | 8.1% | 2026-06-30 |
13F holders
Tracked managers holding TECH at their latest 13F. JSON7 of the 30 tracked managers held TECH at their latest 13F, $216.1M in total at quarter-end prices. Millennium Management is the largest at $79.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.1M | $79.3M | 0.03% | +1.1M |
| Citadel Advisors | 2026-06-30 | 1.1M | $74.2M | 0.01% | +876K |
| Soros Fund Management | 2026-06-30 | 535K | $37.8M | 0.46% | new or n/a |
| D. E. Shaw & Co. | 2026-06-30 | 228K | $16.1M | 0.01% | +200K |
| Two Sigma Investments | 2026-06-30 | 70K | $4.9M | 0.00% | +4K |
| Bridgewater Associates | 2026-06-30 | 27K | $1.9M | 0.01% | +21K |
| AQR Capital Management | 2026-06-30 | 25K | $1.8M | 0.00% | -43K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q4 2026 (quarter ended 2026-06-30) BIO-TECHNE Corp reported revenue of $321.2M, up 1.3% from the same quarter a year earlier. In FY 2026 it generated $292.1M of operating cash flow and spent $41.7M on buybacks and $49.9M on dividends.
- Cash
- $264.7M
- Equity
- $2.11B
- Total assets
- $2.59B
- Shares outstanding
- 156,818,238
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q4 2026derived | 2026-06-30 | $321.2M | n/a | n/a | n/a |
| Q1 2026 | 2026-03-31 | $311.4M | $51.0M | 16.4% | 0.32 |
| Q4 2025 | 2025-12-31 | $295.9M | $38.0M | 12.8% | 0.24 |
| Q3 2025 | 2025-09-30 | $286.6M | $38.2M | 13.3% | 0.24 |
| Q4 2025derived | 2025-06-30 | $317.0M | -$17.7M | -5.6% | n/a |
| Q1 2025 | 2025-03-31 | $316.2M | $22.6M | 7.1% | 0.14 |
| Q4 2024 | 2024-12-31 | $297.0M | $34.9M | 11.7% | 0.22 |
| Q3 2024 | 2024-09-30 | $289.5M | $33.6M | 11.6% | 0.21 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2026 | 2026-06-30 | $1.22B | n/a | $292.1M | $28.9M | $41.7M | $49.9M |
| FY 2025 | 2025-06-30 | $1.22B | $73.4M | $287.6M | $31.0M | $275.7M | $50.4M |
| FY 2024 | 2024-06-30 | $1.16B | $168.1M | $299.0M | $62.9M | $80.0M | $50.4M |
| FY 2023 | 2023-06-30 | $1.14B | $285.3M | $254.4M | $38.2M | $19.6M | $50.3M |
| FY 2022 | 2022-06-30 | $1.11B | $272.1M | $325.3M | $44.9M | $160.9M | $50.2M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-17 from the cover page.
What this page is
BIO-TECHNE Corp in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows BIO-TECHNE Corp (TECH), SEC CIK 842023, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-11.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 842023Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of TECH is sold short?
What is TECH's daily short volume?
Does TECH have fails to deliver?
Are TECH insiders buying or selling?
Who owns more than 5% of TECH?
What did TECH report last quarter?
Which funds hold TECH?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.